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The aim of this study was to estimate the healthcare costs of asthma and chronic obstructive pulmonary disease 
(COPD), in the Netherlands, in 1993. Also studied was the future development of these costs, as a result of ageing 
and possible changes in smoking behavior. 
A prevalence-based cost-of-illness approach was used to estimate direct medical costs. Age- and gender-specific 
data were obtained from representative national registries and large, representative surveys. To model future costs, 
cost estimates were linked to an epidemiological model based on a dynamic multi-state lifetable. It describes 1 yr 
changes, from one state to another, that result from ageing, birth, migration, incidence, recovery from asthma and 
death due to asthma, COPD or other causes, and starting or quitting smoking. Three different scenarios were 
modelled: 1) a reference scenario which primarily predicts the impact of ageing. 2) an ‘attainable’ smoking 
reduction scenario and 3) an ‘extreme’ smoking reduction scenario. 
Direct medical costs were estimated to be SUS 346 million in 1993. With increasing age, the relative importance 
of asthma in total asthma and COPD costs decreased from 91% to less than 4%. Annual costs per patient were 
estimated to be $US 499 for asthma and $US 876 for COPD. The breakdown of costs differed considerably between 
asthma and COPD. 
The reference scenario predicted the costs to increase by 60% to reach $US 555 million by 2010. COPD 
prevention as modelled in the second and the third scenario reduced the projected cost increase from 60% , to 57% 
and 48%, respectively. 
Together, the direct costs of asthma and COPD represent 1.3% of the Dutch health care budget. The breakdown 
of the costs shows different patterns for asthma and COPD. The costs of these diseases are expected to increase by 
60% in the near future. In the short run the impact of smoking reduction on reducing this increase is relatively 
small, but it will be greater in the long run. 
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Introduction 
The importance of asthma and chronic obstructive 
pulmonary disease (COPD), from a health economic point 
of view: is illustrated by the comprehensive body of 
international literature on the economic burden of asthma 
that has emerged since the 1970’s. Cost-of-illness studies of 
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asthma have been conducted in Australia, the U.S.A., the 
U.K., France, Sweden and Canada. These studies were 
recently reviewed by the National Institutes of Health (l), 
who concluded that the direct medical costs of asthma 
currently comprise l-2% of total health care expenditures 
in industrialized countries (1). Dutch data on the costs of 
asthma and COPD have not been published. The direct 
medical costs usually comprise the costs of physician visits, 
medication, inpatient hospital care and emergency room 
care. Sometimes, additional costs such as the costs of 
nursing services, outpatient diagnostic services, ambulance 
use and research are included (2). Although the breakdown 
of medical costs shows that the relative importance of the 
components varies widely among the studies, all studies 
show that the costs of hospitalization and medication are 
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the two largest components, whereas physician costs are 
often the smallest component. In most countries, indirect 
costs account for a similar share of the total costs of asthma 
as the direct medical costs. For indirect costs, most studies 
only measure the costs of productivity losses due to 
morbidity, but one recent study also included the indirect 
costs of premature mortality (2). 
The estimated total per capita costs of asthma in the 
early-nineties’ ranged from 17 SUS yr-’ in Canada to 40 
$US yr-i in Sweden (1,2). The annual costs of asthma per 
affected individual were reported to range from 325 $US in 
Australia to 1315 $US in Sweden (1). These cost figures 
refer to an average case. Costs, however, will differ for 
individual patients depending on the severity of the 
condition and the effectiveness of disease control. Based 
on Canadian data, Sullivan reports the annual costs to vary 
from 76 US$ for a patient with very mild asthma to 1149 
$US for a patient with moderate asthma, and 7399 KJS for 
a patient with very severe asthma (3). Other cost-of-illness 
studies that account for severity mix, however, are missing 
due to the lack of data. 
Barnes et al. have suggested that up to three quarters of 
the total costs of asthma are a result of inadequately 
controlled disease (4). Improving asthma control will 
particularly reduce the need for inpatient hospital and 
emergency care and absence from work. 
There has been only one study of the economic burden of 
COPD (5). It was conducted in Sweden, and showed that in 
1992 the direct medical costs had risen by 44% since 1980. 
Compared to asthma, costs of COPD in Sweden were 
higher for hospital care, similar for outpatient care and 
lower for medication. 
All of the studies mentioned above are prevalence-based 
cost-of-illness studies producing static results for one 
particular year. However, several studies have indicated 
that the prevalence of asthma and chronic obstructive 
pulmonary disease (COPD) has increased in many parts of 
the world over the past two or three decades (1,6,7). Rather 
than knowing the current economic burden of asthma and 
COPD, decision-makers need to know about the expected 
influence of the increasing prevalence on the costs of 
asthma and COPD in the future. 
Therefore the objectives of our study were two-fold. The 
first was to estimate the cost-of-illness associated with 
asthma and COPD in the Netherlands, in 1993, and, where 
possible, to compare asthma with COPD. This estimate 
served as the baseline to which the results of scenarios to 
predict the future changes in healthcare use due to asthma 
and COPD were compared. Modelling these future 
scenarios was the second aim of the study. These first steps 
into dynamic modelling are a particularly useful addition to 
the static results reported in the literature on the costs of 
asthma and COPD so far. 
Data and Methods 
GENERAL COST-OF-ILLNESS APPROACH 
A prevalence-based cost-of-illness approach was used to 
estimate the direct medical costs of asthma and COPD in 
the Netherlands, for the year 1993, from a societal 
perspective. First, an indicator (e.g. general-practitioner 
contacts, hospital inpatient days, day-care treatments, drug 
prescriptions) was identified for each type of healthcare 
resource utilization. Then, data on these indicators were 
extracted from representative national registries for inpa- 
tient care and large, good quality surveys for ambulatory 
care. These data sources were required to provide age, 
gender and diagnosis-specific data. We used six different 
age groups: O-14, 15-24, 2544, 45564, 65-74 and 75+. 
Healthcare service indicators were costed using estimated 
opportunity costs for each unit for resource use. All costs 
were valued in constant 1993 Dutch guilders and converted 
in $US using gross domestic product purchasing power 
parties, as published by the Organisation for Economic Co- 
operation and Development for 1993 (l$US = 2.13 Dutch 
Guilders) (8). When unit prices were from other years, the 
effect of price inflation was removed by using the consumer 
price index to inflate or deflate the data (9). A detailed 
description of the categories of health-care resource 
utilization, the indicators, the data sources and unit costs 
is given in Table 1. 
TABLE 1. Healthcare service indicators, year of registration and units cost 
Indicator Year of registration Unit costs in $US* 
Physicians 
Hospital 
Nursing home 
Medication 
General practitioner Contact 1992-1994 14.55 
Outpatient specialist Contact 199221994 39.44 
General Inpatient day 1993 414.55 
University Inpatient day 1993 813.15 
Asthma centre Inpatient day 1993 312.21 
Day care Treatment day 1993 14085 
Inpatient care Residential day 1993 122.10 
Day care Treatment day 1993 81.69 
Drugs and devices Prescription 1990 33.33 
*Costs in Dutch Guilders were converted to US dollars using the Gross Domestic Product Purchasing Power of NLG 2.13 
per $US in 1993. 
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PHYSICIANS 
The number of contacts with general practitioners (GP) and 
specialized physicians in outpatient clinics was obtained 
from the Health Interview Survey conducted by Statistics 
Netherlands during 1992-1994 (10). Data are reported as 
the average over these three consecutive years. The Health 
Interview Survey is a continuous survey on health state and 
healthcare resource use among a representative sample of 
the Dutch population (11). The Health Interview Survey 
provides age and gender-specific self-reported data on the 
number of people reporting to have ‘Chronic Non-specific 
Lung Disease’ (CNSLD) and their average number of 
contacts with GPs and specialists. Because a distinction 
between asthma and COPD is not made, it was assumed 
that the numbers of age and gender-specific contacts per 
patient were similar for asthma and COPD. This assump- 
tion is based on the recommendation in the Dutch 
guidelines to plan control visits every 3 months for both 
asthma and COPD. To estimate the total number of 
physician contacts in 1993, the age-, gender- and diagnosis- 
specific prevalence was multiplied by the age- and gender- 
specific number of contacts per patient (see section 
‘epidemiological modelling and future scenarios’). 
Unit costs of an average GP-contact were obtained from 
an earlier study (12). Units costs of specialist-contacts were 
estimated by applying the proportion of overall specialist- 
contacts that is associated with asthma and COPD to the 
overall costs of specialist care, and dividing this result by 
the estimated number of specialist-contacts for asthma and 
COPD (13). 
INPATIENT CARE 
The number of admissions to hospitals and the number of 
inpatient days, for asthma or COPD, were obtained from 
the National Medical Registration provided by SIG Health 
Care Information (14). This registration covers almost 
100% of Dutch hospitals and makes an explicit distinction 
between asthma and COPD. Asthma was defined as code 
493 of the International Classification of Disease (ninth 
revision) and COPD was defined as codes 490,49 1 i 492,494 
and 496. 
Patients can also be admitted to one of the five 
specialized Dutch asthma centres, which provide long-term 
multi-disciplinary rehabilitation to patients with asthma or 
COPD whose disease cannot be controlled with the regular 
treatments. Four of these centres are located in the 
Netherlands and one in Switzerland (Davos). Data on the 
number of admissions and the number of inpatient days at 
asthma centres were obtained from the National Medical 
Registration which cover 100% of the asthma centres. 
Again an explicit distinction between asthma and COPD is 
made using the same ICD codes as mentioned above. 
The number of residential nursing-home days and the 
number of day-care treatments were obtained from the 
nursing-home registration by SIG Health Care Information 
(15). This registration covers about 90% of the nursing- 
home beds and day-care facilities. We counted the days and 
treatments associated with the code labelled ‘bronchitis, 
asthma, emphysema and chronic non-specific lung disease’. 
A distinction between these diagnoses is not yet possible. 
Given the high average age of the residents, we assumed 
that 90% of the days and treatments were due to COPD 
and 10% due to asthma. 
The unit costs of an inpatient day in hospitals, asthma 
centres and somatic departments of nursing homes were 
based on the weighted average of the costs per inpatient day 
in institutions of different size published by the National 
Hospital Institute (16-19). We made a distinction between 
university hospitals and general hospitals. Day-care treat- 
ments were valued using charges. 
MEDICATION 
The number of age and gender-specific drug prescriptions 
for respiratory medication was calculated by combining 
data from a 1990 survey on drug prescriptions among a 
large, representative sample of 300 000 inhabitants (20) with 
demographics for 1993 from Statistics Netherlands, More 
specifically, the number of annual prescriptions for 
respiratory medication per capita in a given age/gender 
category was multiplied by the average number of persons 
present during 1993. The age and gender-specific prevalence 
proportions of asthma and COPD were used to divide the 
total number of prescriptions over asthma and COPD. 
The average cost of a prescription for asthma medication 
was obtained from the same study (20). These costs include 
those of devices dispensed by local pharmacists, such as 
inhalers and fixed dispensary fee for prescriptions. 
EPIDEMIOLOGICAL MODELLING AND 
FUTURE SCENARIOS 
For the epidemiological model a dynamic multi-state 
lifetable was used (21). States refer to age, gender, disease 
status and smoking status (never smoker, present smoker 
and former smoker). Several diseases are implemented in 
the model and asthma/COPD is one of the sub-models 
(others being for example lung cancer and coronary heart 
diseases). The starting point is the Dutch population by age 
and gender in 1993 as registered by Statistics Netherlands. 
The asthma/COPD sub-model produces the yearly pre- 
valence of asthma and the yearly prevalence of COPD. It 
describes the 1 yr changes, from one state to another, that 
result from ageing, birth, migration, incidence, recovery 
from asthma and death due to asthma, COPD or other 
causes, and starting or quitting smoking. The initial age and 
gender-specific distribution for never smokers, present 
smokers and former smokers is based on Dutch monitoring 
data on smoking prevalence (22). Information on the 
incidence and prevalence of asthma and the incidence and 
prevalence of COPD was available from a continuous (since 
1971) regional registration among Dutch GPs, which covers 
a population of about 12000 people (23). Asthma was 
defined as code 0860 (asthma/asthmatic bronchitis) and 
COPD as code 1480 (chronic bronchitis including emphy- 
sema) from the E-list. The definitions of asthma and COPD 
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in this list are similar to the definitions used in the 
International Classification of Primary Care (23). The 
population covered by this registration has been shown to 
represent the total Dutch population with respect to age 
and gender. Incidence of asthma and COPD among 
smokers and non-smokers was modelled using registered 
incidence rates and reported relative risks (24). Smoking- 
related relative risks were drawn from the international 
literature (25,26). Asthma recovery and asthma and COPD 
mortality were computed using published recovery rates 
(27) and case fatality rates (13). 
Starting and quitting rates for smoking were the key 
variables in the three different scenarios which we have 
computed: 1) a reference scenario, 2), an ‘attainable’ 
smoking reduction scenario and 3) an ‘extreme’ smoking 
reduction scenario. The first scenario focuses on the impact 
of ageing. Via age- and gender-specific prevalence rates for 
asthma and COPD, demographic change influences the 
dynamics of the costs investigated. The other two scenarios 
focus on the simultaneous impact of ageing and prevention 
of COPD through smoking reduction. Our time-horizon for 
all scenarios is the year 2010. This time-frame has been 
chosen because it is relevant for today’s health policy 
making and the uncertainty with respect to technological 
innovations is limited (as the developmental time of drugs is 
now above 12 yr). Hence, within this time-frame the 
validity of the model assumptions seems acceptable. 
However, readers have to realize that relevant benefits of 
the two smoking reduction scenarios accrue beyond the 
year 2010. 
The reference scenario is a demographic scenario which 
assumes that age and gender-specific starting and quitting 
rates for smoking as registered for 1993 remain constant 
during future years. These rates are shown in Table 2. Since 
the distribution of the population shifts towards age 
categories with lower starting rates and higher quitting 
TABLE 2. Age and gender-specific starting and quitting rates 
for smoking in 1993 used in the reference scenario 
Age Starting rate Cessation rate 
Male Female Male Female 
-10 0 0 0 0 
lo-14 72/1000 23/1000 0 0 
15-19 s7/1000 47/1000 41/1000 46jlOOO 
20-24 45/1000 31/1000 41/1000 34/1000 
25-29 30/1000 20/1000 34/1000 29/1000 
30-34 18/1000 12/1000 28/1000 27/1000 
35-39 0 0 16/1000 7/1000 
4044 0 0 19/1000 9jlOOO 
4549 0 0 22/1000 10/1000 
50-54 0 0 25/1000 12/1000 
55-59 0 0 29/1000 12/1000 
60-64 0 0 33/1000 15/1000 
65+ 0 0 0 0 
Source: StiVoRo, 1997 (22). 
rates, the proportion of the Dutch population that is 
smoking is reduced from 32.8% in 1993 to 30.4% in 2010. 
The key assumptions regarding smoking behaviour in the 
two smoking reduction scenarios are given in Table 3. The 
‘attainable’ smoking reduction scenario (27) assumes that 
through continuous health promotion people are demoti- 
vated to start smoking, resulting in a 20% reduction of the 
starting rate in each age and gender-specific group over a 
3 yr period (1998-2000). This 20% reduction is maintained 
through periodic campaigns. It is further assumed that in 
1998, an additional 14% of the smokers quit, over and 
above the trend, whereas for later years an additional 
annual quitting rate of only 2% is assumed. These 
assumptions would reduce the percentage of smokers to 
20.5% in 2010. The assumptions in this scenario are 
realistic. Several studies of the effects of smoking preven- 
tion have shown a 20% reduction of the starting rate (29). 
Other studies have shown that a 14% increase of the 
quitting rate in the first year after the campaign is 
achievable (30,31). 
The ‘extreme’ and rather theoretical, smoking reduction 
scenario assumes that a successful anti-smoking campaign 
was already started in 1990 leading to a 40% reduction of 
the starting rate and 14% increase in the quitting rate in 
that year. For the years post-1990, this scenario assumes 
that an additional 7% of the smokers would annually quit. 
These assumptions reduce the percentage of smokers to 
only 8% in 2010. 
Resource utilization is assumed to develop proportion- 
ally with the developments in age- and gender-specific 
prevalence. Thus, the projections into the future do not 
account for change in treatment patterns, such as an 
increased prescription of new classes of inhaled steroids or 
long-acting bronchodilators. 
Results 
BURDEN AND COST OF ILLNESS 
Table 4 presents the burden of illness and the costs of 
healthcare associated with asthma and COPD in 1993, in 
The Netherlands. Total costs of illness were estimated to be 
$US 346 million, representing 1~3% of the total Dutch 
healthcare budget in 1993 (9). This corresponds to $US 555 
per patient and $US 23 per capita. The cost of inpatient 
hospital care (including asthma centres) covered about 57% 
of all medical costs and medications accounted for about 
29% of the costs. The costs of outpatient care provided by 
GPs and specialized physicians each accounted for less then 
5% of the total costs of asthma and COPD. Aggregated 
hospital costs (including asthma centres) were estimated to 
be about $US 198 million, representing 2.4% of total Dutch 
hospital expenditures in 1993. Expenditures on asthma and 
COPD drugs were estimated to account for almost 4% of 
total Dutch drug expenditures in 1993. 
Figures 1 and 2 show the association between direct 
medical costs and age. Fig. 1 shows that, apart from the 
youngest and oldest age group, the annual costs per patient 
increase with age from $US 195 patients between 15-25 yr 
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TABLE 3. Scenario assumptions and outcome on smoking behaviour: percentage decrease in starting rate, percentage increase 
in quitting rate and percentage of smokers in the total population (> 10 years of age) in 2010 
Additions to the reference scenario 
Attainable smoking reduction scenario Extreme smoking reduction scenario 
Decrease in starting rate 20% 40% 
Increase in quitting rate 14% in 1998 14% in 1990 
2% in later years 7% in later years 
% smokers in 2010 20.5% 8% 
In 1993 32.8% of the Dutch population was smoking. The reference scenario predicts that in 2010 30.4% of the Dutch 
population will be smoking. 
TABLE 4. Burden and cost of illness associated with asthma and chronic obstructive pulmonary disease in The Netherlands in 
1993 
Utilization, absolute and per 1000 inhabitants Costs in $US* % 
Prevalence 
Physician 
Hospital 
Nursing home 
Medication 
Total 
Asthma 
COPD 
General practitioner 
Specialist 
Inpatients 
Day Care 
Asthma centre 
Inpatient 
Day care 
309 113 patients; 20/1000 
314 634 patients; 21/1000 
652 393 contacts; 43/1000 13 541 986 3.9% 
397 103 contacts; 26/1000 15 660 418 4.5% 
381 194 days; 25/1000 166 969 510 48.2% 
1032 treatments; 0.07/1000 145 352 0.04% 
99 114 days; 6/1000 30 944 042 8.9% 
163 196 days; ll/lOOO 19 920 638 5.8% 
130 treatments; 0~008/1000 10 620 0.003 % 
2 975 349 prescriptions; 194/1000 98 912 911 286% 
346 105 450 100% 
*Costs in Dutch Guilders were converted to US dollars using the Gross Domestic Product Purchasing Power of NLG 2.13 
per $US. 
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FIG. 1. Annual costs per patient in 1993 $US. 
to more than $US 1100 for patients between 65 and 74. 
Figure 2 shows that the relative importance of asthma in 
total asthma/COPD costs decreases as age progresses. The 
proportion of the total costs that is due to asthma 
decreases from 9 1% at ages 15525 to less than 4% at ages 
over 65. 
DIFFERENCE BETWEEN ASTHMA AND 
COPD 
Annual costs were estimated to be $US 293 per asthma 
patient and $US 813 per COPD patient. COPD accounted 
for 86% of total inpatient hospital costs whereas asthma 
accounted for only 14% of these costs. The higher costs of 
inpatient treatment for COPD reflect both a higher number 
of hospital admissions and a longer duration of hospitali- 
zation. For every hospital admission for asthma there were 
3.5 hospital admissions for COPD. The average length of 
stay equalled 9.2 days for asthma and 16.0 days for COPD. 
The average number of inpatient hospital days was 0.17 per 
asthma patient and 0.97 per COPD patient. At increasing 
age, the number of hospital admissions and inpatient days 
for asthma decrease, whereas the number of admissions and 
days for COPD increase. 
COPD also accounted for 63% of the cost of outpatient 
specialized physicians, 59% of the costs of medications and 
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FIG. 2. Relative importance of asthma and COPD in total 
1993 costs by age. q : COPD; n : asthma. 
60% of the costs of treatment in asthma centres. The ratio 
of admissions to these centres for asthma compared to 
COPD was 1:2.4. The number of days spent in an asthma 
centre is 50% higher for men than for women. Women are 
more frequently referred because of asthma, whereas men 
are more frequently referred because of COPD. 
Figure 3 shows a breakdown of the costs of asthma and 
COPD separately. In COPD, inpatient hospital care is the 
largest component (57%) of direct medical costs, whereas in 
asthma, medications account for the greatest part (45%) of 
these costs. 
SCENARIOS 
In the reference scenario, the prevalence of asthma and 
COPD is projected to increase from 623 700 in 1993 to 
more than 1 million in 2010. This corresponds to an 
increase from about 41 per 1000 inhabitants in 1993 to 
about 61 per 1000 inhabitants in 2010. Assuming constant 
treatment patterns and costs of care, the reference scenario 
predicts direct medical costs to increase from $US 346 
million in 1993 to $US 555 million in 2010, an increase of 
60%. About 75% of this increase can be explained by the 
increase in prevalence of COPD from 20 per 1000 
inhabitants in 1993 to 31 per 1000 inhabitants in 2010. 
The rest results from an increase in the prevalence of 
asthma. 
Compared to the reference scenario, the ‘attainable’ 
smoking reduction scenario reduces the prevalence in 2010 
with 2.6% or 27000 patients. The corresponding costs 
reduce from $US 555 million in 2010 (based on the 
reference scenario) to $US 544 million in 2010 (based on 
the ‘attainable’ scenario). This reduction is relatively small 
because the projection was limited to the year 2010, 
whereas the savings from smoking reduction accrue far 
beyond that year. 
In the ‘extreme’ smoking reduction scenario, the pre- 
valence in 2010 was projected to decrease with 8~3% or 
92000 patients, when compared to the reference scenario. 
The corresponding direct medical costs of asthma and 
COPD were projected to decrease to $US 514 million, 
which is a reduction of 7.5% compared to the reference 
Asthma 
I 
Copd 
7 3 4 
23 
FIG. 3. Relative contribution of various types of resource 
use to the total costs of asthma and COPD separately. q 
medication; hospital; q asthma centre; q general 
practitioner; [7: specialist; n : nursing home. 
scenario and a reduction of 5.6% compared to the 
‘attainable’ smoking reduction scenario. 
Figure 4 compared the three scenarios with respect to the 
predicted increase in costs between 1993 and 2010 for the 
various types of resource use. It shows that ageing (the 
reference scenario) has the largest impact on drug use and 
inpatient hospital care, which costs increase with 71% and 
60%, respectively. These two types of resource use also 
show the largest reduction in costs resulting from the two 
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FIG. 4. Increase in costs: 2010 compared to 1993 according 
to three different scenarios. n : references; q feasible 
smoking reduction; 0: optimistic smoking reduction 
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smoking reduction scenarios. In the most extreme scenario, 
the increase in costs of medications and inpatient hospital 
care is reduced to 56% and 46%, respectively. 
Conclusion and discussion 
COST-OF-ILLNESS 
Total cost-of-illness due to asthma and COPD were 
estimated to be SUS 346 million, representing 1.3% of the 
total Dutch health budget, in 1993. The costs of inpatient 
hospital care were by far the single largest component of 
medical costs (57%), followed by drug costs (29%). With 
increasing age, the relative importance of asthma in total 
asthma and COPD costs decreased from 91% to less than 
4%. Annual costs were estimated to be SUS 499 per asthma 
patient and $US 876 per COPD patient. The breakdown of 
total costs showed different patterns for asthma and 
COPD. The costs of medication accounted for 45% of 
the total costs of asthma, but only 23% of the total costs of 
COPD. The costs of inpatient hospital care accounted for 
57% of the total costs of COPD, whereas they accounted 
for only 27% of the total costs of asthma. The costs of 
inpatient hospital care were almost six times higher for 
COPD than for asthma. Compared to asthma, COPD 
patients are more frequently hospitalized (1:35) and their 
average length of stay is almost twice as long. 
This study focused on direct medical costs. Costs 
associated with production loss due to absence from work 
because of temporary morbidity (indirect costs) were not 
taken into account. The reason is that diagnosis-related 
sick-leave data are very unreliable in the Netherlands, 
because absence from work shorter than 6 weeks is not 
included in the statistics. Another limitation of this study is 
that the costs of emergency departments, home care and 
ambulance transportations were not taken into account 
because data were lacking. Finally, 1992-1994 resource use 
data were used, since for some categories of resource use 
more recent data were not available. 
A nation-wide cost-of-illness study that ranked 62 
diagnoses according to their share of the total health-care 
costs was published in 1997 (32). It showed that, in men, 
asthma and COPD were responsible for 2.4% of total 
healthcare costs and ranked seventh after mental handi- 
caps, dental problems, symptoms and unexplained diseases, 
coronary heart diseases, cerebrovascular accidents and 
dementia. In women, the cost of asthma and COPD ranked 
thirteenth with 1.2% of total healthcare costs. Comparing 
this study with our study is not valid since they used a top- 
down approach to divide total healthcare costs in The 
Netherlands in 1994 over 62 diagnoses. This implies that 
they have included different assumptions, different data 
sources, different cost components, etc. Furthermore? they 
did not distinguish between asthma and COPD. 
Uncertainties are inherent to estimates of costs of illness. 
The data for cost-of-illness studies are usually taken on an 
aggregate level from routine registries and/or surveys. 
Inadequate sampling and recall bias may affect survey data 
and imprecision in the definitions of asthma, and COPD 
may affect survey data as well as data from large national 
registries. It is common in this area to experience difficulties 
in differentiating between asthma and COPD. From a 
clinical point of view, asthma and COPD are currently 
considered to be different health conditions in The Nether- 
lands. The ‘Dutch hypothesis’ that both conditions are 
different expressions of the same underlying disease, called 
chronic non-specific lung disease, has been abandoned (33) 
and different guidelines for the management of asthma and 
COPD are being used. Nevertheless, every physician will 
admit that the two diseases are often hard to distinguish 
because many patients have characteristics of both asthma 
and COPD at the same time. From an epidemiological 
point of view it is therefore relevant to present the overall 
costs of both diseases. 
Although we have used the best available data, it was 
unavoidable to make some assumptions in order to 
separate the costs of asthma and COPD. One assumption 
was that the number of physician contacts and drug 
prescriptions per age/gender category were the same for 
asthma and COPD. Though the age/gender-specific con- 
tacts were assumed the same for asthma and COPD, they 
were multiplied with the respective prevalence, thus 
contributing to cost differentials. The age/gender specific 
prevalence proportions of asthma and COPD had to be 
used to separate the cost of medications. The largest 
component of cost - the costs of inpatient care - was not 
affected by this type of assumption. The routine national 
registries on hospital care and care provided by asthma 
centres explicitly distinguish asthma from COPD and they 
cover almost 100% of the Dutch hospitals. Despite some 
limitations resulting from the assumptions this study 
enabled us to identify the differences in cost distributions 
between asthma and COPD. Moreover, the assumptions on 
drug prescriptions and physician contacts are reasonable 
given that asthma and COPD patients use the same type of 
medication and the guidelines for both diseases recommend 
routine control visits every 3 months. 
MODELLING FUTURE SCENARIO 
We have used the prevalence-based cost-of-illness study as 
a starting point to compare future trends in disease 
prevalence. The estimated cost-of-illness in 1993 provided 
a baseline for our modelling approach. We have developed 
an epidemiological model that allows us to predict the 
development of the healthcare costs in the future and to 
study the impact of changes in demographics, risk factors 
and treatment patterns on these future costs. Currently, 
ageing and smoking are the only risk factors included in our 
model. These were the key variables in the three different 
scenarios that we have presented in this paper. 
The first scenario was the reference scenario, which 
primarily reflected the impact of ageing. It predicted direct 
medical costs to increase by 60% from $US 346 million in 
1993 to $US 555 million in 2010. The largest increase was 
predicted for drug use (+71%) and inpatient hospital care 
(+60%). The second and third scenarios were the ‘attain- 
able’ smoking reduction scenario and the ‘extreme’, rather 
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theoretical, smoking reduction scenario, which reduced the 
projected increase in direct medical costs from 60%, to 
57% and 48%, respectively, as a result of COPD 
prevention. The greatest reductions were found in the costs 
of medications and inpatient hospital care. The two 
scenarios merely describe the benefits as compared to the 
reference scenario. Since we have not yet taken into account 
the additional costs of the smoking reduction campaigns, 
these benefits cannot be regarded as net savings. Also, we 
have not taken into account the health gains achieved. 
Inclusion of both would require a full economic evaluation. 
The increase in direct medical costs as predicted by the 
various scenarios is likely to be underestimated because we 
have assumed that treatment patterns and unit prices of 
care have remained constant at the 1993 level. However, 
between 1990 and 1996 the annual increase in Dutch health- 
care costs was on average about 6% (34). This increase is 
caused by both increasing volumes and increasing prices. 
The annual increase in price level is 2.85%. In our scenario 
analyses we have already taken into account the volume 
increases that are associated with the increasing prevalence 
of asthma and COPD. If the increase in price level of 2.85% 
per year would have been taken into account, the reference 
scenario would predict the costs to increase from $US 346 
million in 1993, to over $US 800 million instead of $US 555 
in 2010. Thus, instead of a 60% increase the reference 
scenario would predict a 109% increase. 
The prevalence predicted by the model was validated 
against the actual prevalence of asthma and COPD as 
recorded in the GP registration during the years 1990 to 
1993. The prevalence predicted by the model was somewhat 
lower than the registered prevalence. It was on average 4% 
lower for males and 10% lower for females during these 
4 yr. Hence, our predictions of the future increase in 
prevalence and healthcare costs seem to be rather con- 
servative. 
The impact of the two smoking reduction scenarios on 
healthcare costs of COPD might seem smaller than 
expected. The reason is that we did not show projections 
beyond the year 2010. Since smoking reduction at a 
younger age will decrease the risk of developing COPD at 
an older age, there is a considerable time-lag between 
intervention and health gain. The health gains that result 
from a reduction of the smoking rate will be much greater 
in the years after 2010. We chose, however, a medium-term 
time-horizon which integrates a framework of rather 
realistic technological constraints with a feasible planning 
period for health policy making. The time-lag for the health 
gains that result from increasing the quitting rate is 
substantially shorter. 
Since the effects of smoking reduction seem to be 
relatively limited in the medium-term, additional efforts to 
reduce the costs are needed. Such efforts should be directed 
towards reduction of the costs of medication and inpatients 
hospital care, the two areas where the future growth and 
potential gain might be greatest. Because the impact of 
ageing is substantially greater in COPD than in asthma, 
special attention should be given to reducing the expected 
increase in the costs of COPD. It has been suggested that 
savings can be achieved by improving self-management 
skills and the adherence to the treatment guidelines, and 
hence by improving the levels of disease control. Although 
it has been shown that self-management education for adult 
asthmatics can reduce resource use (35), it is likely that 
increased efforts to manage asthma and COPD more 
appropriately will not immediately result in net cost 
reductions. For example, it has been shown that although 
substitution of bronchodilator medication by the more 
appropriate combination of bronchodilator medication 
with anti-inflammatory medication in asthma was asso- 
ciated with significant health gains, it was not associated 
with net savings in medical costs, although such savings 
might be expected in the long run (36). Another option to 
reduce the costs might be to shift the management of 
COPD exacerbations from the inpatients setting towards 
the home care setting. The available evidence does not 
clearly indicate whether such shift would indeed reduce the 
costs to the healthcare system. 
The benefits of the two smoking reduction scenarios go 
beyond reducing the incidence of COPD. These scenarios 
also reduce the incidence of other smoking-related disease 
like cardiovascular diseases and lung cancer. However, the 
health benefits of smoking reduction cannot automatically 
be translated into financial benefits for the healthcare 
sector at large. Even though the healthcare costs of 
smokers at a given age are higher than those of non- 
smokers at the same age, the non-smokers live longer and 
may accumulate more healthcare costs than smokers, 
especially at advanced age (37). In the future we should 
study the impact of smoking reduction on the smoking- 
related diseases simultaneously. The structure of our model, 
which consists of an overall demographic module and 
several chronic disease sub-modules makes it possible to 
study the impact of competing morbidity and competing 
mortality risks, i.e. when subjects live longer because they 
do not get COPD, they may get another disease and die 
from that disease. 
In this paper we have investigated the implications of 
highly relevant policy options, i.e. anti-smoking policies by 
appropriate modelling, processing the best available data. 
We have shown that the costs of asthma and COPD are, at 
least in the medium-term, not very sensitive to changes in 
smoking behavior alone. The health problem faced today is 
that demographic change is expected to significantly 
increase these costs in the coming years. Accordingly, 
better forms of preventive action must be sought, and other 
ways of controlling the costs of care for asthma and COPD 
must be investigated. 
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